Ionis Pharmaceuticals, Inc. Long-Term Debt, Maturity, Year Five
Ionis Pharmaceuticals, Inc. (IONS) had Long-Term Debt, Maturity, Year Five of $770.06 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Four and Five
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive · last filed 2026-02-26
- 2025-12-31: Long-Term Debt, Maturity, Year Five $770.06M.
- 2024-12-31: Long-Term Debt, Maturity, Year Five $60.00K.
- 2023-12-31: Long-Term Debt, Maturity, Year Five $580.28M.
- 2022-12-31: Long-Term Debt, Maturity, Year Five $447.00K.
| Period end | Long-Term Debt, Maturity, Year Five |
|---|---|
| 2025-12-31 | $770.06M 10-K · filed 2026-02-26 |
| 2024-12-31 | $60.00K 10-K · filed 2025-02-19 |
| 2023-12-31 | $580.28M 10-K · filed 2024-02-21 |
| 2022-12-31 | $447.00K 10-K · filed 2023-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |